Gut microbiota-driven drug metabolism in inflammatory bowel disease
- PMID: 32652007
- PMCID: PMC7904070
- DOI: 10.1093/ecco-jcc/jjaa143
Gut microbiota-driven drug metabolism in inflammatory bowel disease
Abstract
Background and aims: The gut microbiota plays an important role in the metabolization and modulation of several types of drugs. With this study we aimed to review the literature about microbial drug metabolism of medication prescribed in inflammatory bowel disease practice.
Methods: A systematic literature search was performed in Embase and PubMed from inception to October 2019. The search was conducted with predefined MeSH/Emtree and text terms. All studies about drug metabolism by microbiota of medication prescribed in inflammatory bowel disease practice were eligible. A total of 1018 records were encountered and 89 articles were selected for full text reading.
Results: Intestinal bacterial metabolism or modulation is of influence in four specific drugs used in inflammatory bowel disease (mesalazines, methotrexate, glucocorticoids and thioguanine). The gut microbiota cleaves the azo-bond of sulfasalazine, balsalazide and olsalazine and releases the active moiety 5-aminosalicylic acid. It has an impact on the metabolization and potentially on the response of methotrexate therapy. Especially thioguanine can be converted by intestinal bacteria into the pharmacological active 6-thioguanine nucleotides without the requirement of host metabolism. Glucocorticoid compounds can be prone to bacterial degradation.
Conclusion: The human intestinal microbiota can have a major impact on drug metabolism and efficacy of medication prescribed in inflammatory bowel disease practice. A better understanding of these interactions between microbiota and drugs is needed and should be an integral part of the drug development pathway of new inflammatory bowel disease medication.
Keywords: Drug Metabolism; Inflammatory bowel disease; Microbiota.
© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.
Figures
Similar articles
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Health professionals' experience of teamwork education in acute hospital settings: a systematic review of qualitative literature.JBI Database System Rev Implement Rep. 2016 Apr;14(4):96-137. doi: 10.11124/JBISRIR-2016-1843. JBI Database System Rev Implement Rep. 2016. PMID: 27532314
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
Stem cell transplantation for induction of remission in medically refractory Crohn's disease.Cochrane Database Syst Rev. 2022 May 13;5(5):CD013070. doi: 10.1002/14651858.CD013070.pub2. Cochrane Database Syst Rev. 2022. PMID: 35556242 Free PMC article.
Cited by
-
Novel Techniques and Models for Studying the Role of the Gut Microbiota in Drug Metabolism.Eur J Drug Metab Pharmacokinet. 2024 Mar;49(2):131-147. doi: 10.1007/s13318-023-00874-0. Epub 2023 Dec 21. Eur J Drug Metab Pharmacokinet. 2024. PMID: 38123834 Review.
-
Cardiovascular Diseases and Pharmacomicrobiomics: A Perspective on Possible Treatment Relevance.Biomedicines. 2021 Sep 28;9(10):1338. doi: 10.3390/biomedicines9101338. Biomedicines. 2021. PMID: 34680455 Free PMC article. Review.
-
Antibiotics in the pathogenesis of diabetes and inflammatory diseases of the gastrointestinal tract.Nat Rev Gastroenterol Hepatol. 2023 Feb;20(2):81-100. doi: 10.1038/s41575-022-00685-9. Epub 2022 Oct 18. Nat Rev Gastroenterol Hepatol. 2023. PMID: 36258032 Free PMC article. Review.
-
Mesalamine-Mediated Amelioration of Experimental Colitis in Piglets Involves Gut Microbiota Modulation and Intestinal Immune Cell Infiltration.Front Immunol. 2022 Jul 8;13:883682. doi: 10.3389/fimmu.2022.883682. eCollection 2022. Front Immunol. 2022. PMID: 35898495 Free PMC article.
-
Gut bacteria and the host synergies promote resveratrol metabolism and induce tolerance in ALD mice.NPJ Biofilms Microbiomes. 2025 Jul 14;11(1):132. doi: 10.1038/s41522-025-00766-y. NPJ Biofilms Microbiomes. 2025. PMID: 40659696 Free PMC article.
References
-
- Aggeletopoulou I, Konstantakis C, Assimakopoulos SF, Triantos C. The role of the gut microbiota in the treatment of inflammatory bowel diseases. Microb Pathog 2019;137:103774. - PubMed
-
- Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, Basit AW. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 2008;363:1–25. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources